Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics : a systematic review and meta-analysis. / Šuler Baglama, Špela; Peteln, Irena; Jemec, Gregor B.E.
I: Journal of Dermatological Treatment, Bind 33, Nr. 8, 2022, s. 3136-3142.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics
T2 - a systematic review and meta-analysis
AU - Šuler Baglama, Špela
AU - Peteln, Irena
AU - Jemec, Gregor B.E.
N1 - Publisher Copyright: © 2022 Taylor & Francis Group, LLC.
PY - 2022
Y1 - 2022
N2 - Background: Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil. Similar observations using different chemotherapeutics may point to other drugs with a potential for repositioning. Objective: This systematic review aims to evaluate chemotherapeutic agents linked to inflammation-induced cure of AK. Methods: This systematic review was registered in PROSPERO (CRD42022346168) and followed PRISMA guidelines. A comprehensive literature search for eligible original articles written in English and published in peer-reviewed journals until July 13, 2022 was conducted in MEDLINE and Embase. Results: 28 articles met inclusion criteria accounting for 36 patients (mean age 68.4 ± 8.3 years) with inflamed AK, exposed to 21 different chemotherapeutic agents–21/36 (58.3%) received monotherapy and 15/36 (41.7%) received multidrug combinations. Regression was complete in 13/28 (46.4%) and partial in 14/28 (50.0%) of inflamed AK. Cure rates of inflamed AK in multidrug combinations were not superior to monotherapies (p =.252), leading to the observation that the majority of the former (14/15; 93.3%) encompassed one of five chemotherapeutic agents linked to AK inflammation also as a monotherapy. Conclusion: Overall, inflammation partially/completely cured AK in 96.4% of patients (27/28). Taxanes, pemetrexed, and doxorubicin might have the potential for the management of AK.
AB - Background: Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil. Similar observations using different chemotherapeutics may point to other drugs with a potential for repositioning. Objective: This systematic review aims to evaluate chemotherapeutic agents linked to inflammation-induced cure of AK. Methods: This systematic review was registered in PROSPERO (CRD42022346168) and followed PRISMA guidelines. A comprehensive literature search for eligible original articles written in English and published in peer-reviewed journals until July 13, 2022 was conducted in MEDLINE and Embase. Results: 28 articles met inclusion criteria accounting for 36 patients (mean age 68.4 ± 8.3 years) with inflamed AK, exposed to 21 different chemotherapeutic agents–21/36 (58.3%) received monotherapy and 15/36 (41.7%) received multidrug combinations. Regression was complete in 13/28 (46.4%) and partial in 14/28 (50.0%) of inflamed AK. Cure rates of inflamed AK in multidrug combinations were not superior to monotherapies (p =.252), leading to the observation that the majority of the former (14/15; 93.3%) encompassed one of five chemotherapeutic agents linked to AK inflammation also as a monotherapy. Conclusion: Overall, inflammation partially/completely cured AK in 96.4% of patients (27/28). Taxanes, pemetrexed, and doxorubicin might have the potential for the management of AK.
KW - actinic keratoses
KW - Chemotherapy
KW - inflammation
KW - treatment
U2 - 10.1080/09546634.2022.2131298
DO - 10.1080/09546634.2022.2131298
M3 - Review
C2 - 36190770
AN - SCOPUS:85139799975
VL - 33
SP - 3136
EP - 3142
JO - Journal of Dermatological Treatment
JF - Journal of Dermatological Treatment
SN - 0954-6634
IS - 8
ER -
ID: 328732922